The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, or systemic lupus erythematosus.La présente invention concerne une méthode de traitement d'un sujet atteint d'une forme de sclérose en plaques ou présentant un syndrome cliniquement isolé comprenant une administration périodique d'une quantité d'un anticorps anti-CD20 au moins deux fois au sujet, que l'on fait suivre par une administration périodique d'une quantité d'acétate de glatiramère au sujet, les quantités étant efficaces pour traiter le sujet.
